Immunological Basis of Etiopathogenesis and Treatment of Bronchiectasis
Keywords:
bronchiectasis, respiratory infections, inflammation, immune response, immunological approachesAbstract
Bronchiectasis is characterized by a constant and abnormal expansion of the airways of the lungs (bronchi) and/or a violation of the tone of the muscle layer of the bronchial wall due to inflammation, sclerosis, dystrophy, hypoplasia. Bronchiectasis is a very common disease that is the main cause of respiratory problems. A deficiency in the host's immune response to bacterial infection is considered to be the main condition for the development of bronchiectasis. In addition, many patients have no identifiable cause and are defined as having an idiopathic disease. This can lead to the development of a chronic respiratory tract infection and subsequent inflammation. Patients tend to have persistent disease despite aggressive use of antibiotics and optimal sputum clearance techniques. New therapies based on the manipulation of the immune response are becoming available and offer significant promise for the treatment of this condition.
References
Ходош Э.М. Бронхоэктатическая болезнь: Учебное пособие для самостоятельной работы пульмонологов, торакальных хирургов, фтизиатров, терапевтов и врачей общей практики [Текст] / Э.М. Ходош. — Х., 2018. — 71 с.: ил.
Weycker D., Hansen G. L., Seifer F. D. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chronic Respiratory Disease. 2016;14(4):377–384.
Polverino E., Cacheris W., Spencer C., Operschall E. In O'Donnell AE: Global burden of non-cystic fibrosis bronchiectasis: A simple empidemiologic analysis. 2012.
Khikmatov, J. S., Khudaibergenov Sh. N., Khamdamov B. Z., Ismatov J. K. "Bronchiectasis (literature review)." Scientific progress 2.7 (2021): 94-108.
Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and Economic Burden of Bronchiectasis. Clinical Pulmonary Medicine. 2005;12(4):205-209
Hikmatov J.S. "Bronchiectasis disease: etiology, pathogenesis, modern diagnosis and treatment." Новости образования: исследование в XXI веке 1.3 (2022): 1048-1064.
Martínez-García M. Á., Soler-Catalunã J. J., Sanz Y. D., et al. Factors associated with bronchiectasis in patients with COPD. CHEST. 2011;140(5):1130–1137.
King PT. The Role of the Immune Response in the Pathogenesis of Bronchiectasis. Biomed Res Int. 2018;2018:6802637.
Redondo M., Keyt H., Dhar R., Chalmers J. D. Global impact of bronchiectasis and cystic fibrosis. Breathe. 2016;12(3):222–235.
Quinti I., Soresina A., Spadaro G., et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. Journal of Clinical Immunology. 2007;27(3):308–316.
Pasteur M. C., Helliwell S. M., Houghton S. J., et al. An investigation into causative factors in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2000;162(4):1277–1284.
Vendrell M., de Gracia J., Rodrigo M.-J., et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. CHEST. 2005;127(1):197–204.
Zimmer J., Andrès E., Donato L., Hanau D., Hentges F., de la Salle H. Clinical and immunological aspects of HLA class I deficiency. QJM: Monthly Journal of the Association of Physicians. 2005;98(10)
Chalmers J. D., McHugh B. J., Doherty C., et al. Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study. The Lancet Respiratory Medicine. 2013;1(3):224–232.
Paulson M. L., Freeman A. F., Holland S. M. Hyper IgE syndrome: An update on clinical aspects and the role of signal transducer and activator of transcription 3. Current Opinion in Allergy and Clinical Immunology. 2008;8(6):527–533.
Kearney P. J., Kershaw C. R., Stevenson P. A. Bronchiectasis in acute leukaemia. British Medical Journal. 1977;2(6091):857–859.
Knowles G. K., Stanhope R., Green M. Bronchiectasis complicating chronic lymphatic leukaemia with hypogammaglobulinaemia. Thorax. 1980;35(3):217–218.
Chen L. W., McShane P. J., Karkowsky W., et al. De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. CHEST. 2017;152(3):683–685.
Basnayake T. L., Morgan L. C., Chang A. B. The global burden of respiratory infections in indigenous children and adults: A review. Respirology. 2017;22(8):1518–1528.
Chang A. B., Marsh R. L., Upham J. W., et al. Toward making inroads in reducing the disparity of lung health in Australian indigenous and new zealand maori children. FrontPediatr. 2015;3:9
Singleton R., Morris A., Redding G., et al. Lewis C: Bronchiectasis in Alaska Native children: causes and clinical courses. PediatrPulmonol. 2000;29(3):182–187.
Watt A. P., Brown V., Courtney J., et al. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax. 2004;59(3):231–236.
Whitters D., Stockley R. Immunity and bacterial colonisation in bronchiectasis. Thorax. 2012;67(11):1006–1013.
Simpson J. L., Grissell T. V., Douwes J., Scott R. J., Boyle M. J., Gibson P. G. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax. 2007;62(3):211–218.
Salvator H., Mahlaoui N., Catherinot E., et al. Pulmonary manifestations in adult patients with chronic granulomatous disease. European Respiratory Journal. 2015;45(6):1613–1623.
Ho J. C., Tipoe G., Zheng L., et al. In vitro study of regulation of IL-6 production in bronchiectasis. Respiratory Medicine. 2004;98(4):334–341.
Zheng L., Shum I. H., Tipoe G. L., et al. Macrophages, neutrophils and tumour necrosis factor-α expression in bronchiectatic airways in vivo. Respiratory Medicine. 2001;95(10):792–798.
Hodge S., Hodge G., Jersmann H., et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2008;178(2):139–148.
Shum D. K. Y., Chan S. C. H., Ip M. S. M. Neutrophil-mediated degradation of lung proteoglycans: Stimulation by tumor necrosis factor-α in sputum of patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2000;162(5):1925–1931.
Chalmers J. D., Moffitt K. L., Suarez-Cuartin G., et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2017;195(10):1384–1393.
Tsang K. W., Chan K.-N., Ho P.-L., et al. Sputum elastase in steady-state bronchiectasis. CHEST. 2000;117(2):420–426.
Brinkmann V., Laube B., Abu Abed U., Goosmann C., Zychlinsky A. Neutrophil extracellular traps: how to generate and visualize them. Journal of Visualized Experiments. 2010;(36)
King P. T., Sharma R., O'Sullivan K. M., et al. Deoxyribonuclease 1 reduces pathogenic effects of cigarette smoke exposure in the lung. Scientific Reports. 2017;7(1)
Boyton R. J., Smith J., Ward R., et al. HLA-C and killer cell immunoglobulin-like receptor genes in idiopathic bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2006;173(3):327–333.
McDonnell M. J., Anwar G. A., Rutherford R. M., et al. Lack of association between KIR and HLA-C type and susceptibility to idiopathic bronchiectasis. Respiratory Medicine. 2014;108(8):1127–1133.
Whitwell F. A study of the pathology and pathogenesis of bronchiectasis. Thorax. 1952;7(3):213–239.
Sepper R., Konttinen Y. T., Ingman T., Sorsa T. Presence, activities, and molecular forms of cathepsin G, elastase, α1-antitrypsin, and α1-antichymotrypsin in bronchiectasis. Journal of Clinical Immunology. 1995;15(1):27–34.
Frija-Masson J., Martin C., Regard L., et al. Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis. European Respiratory Journal. 2017;49(4):p. 1601873.
Boyton R. J., Altmann D. M. Bronchiectasis: Current Concepts in Pathogenesis, Immunology, and Microbiology. Annual Review of Pathology: Mechanisms of Disease. 2016;11:523–554.
Tan H.-L., Regamey N., Brown S., Bush A., Lloyd C. M., Davies J. C. The Th17 pathway in cystic fibrosis lung disease. American Journal of Respiratory and Critical Care Medicine. 2011;184(2):252–258.
Clementi C. F., Murphy T. F. Non-typeable Haemophilus influenzae invasion and persistence in the human respiratory tract, Frontiers in Cellular and Infection Microbiology. 2011;1, article 1
Pizzutto S. J., Yerkovich S. T., Upham J. W., et al. Children with chronic suppurative lung disease have a reduced capacity to synthesize interferon-gamma in vitro in response to non-typeable Haemophilus influenzae. PLoS ONE. 2014;9(8)
King P. T., Lim S., Pick A., et al. Lung T-cell responses to nontypeable Haemophilus influenzae in patients with chronic obstructive pulmonary disease. The Journal of Allergy and Clinical Immunology. 2013;131(5):1314–1321.
Prezzemolo T., Guggino G., la Manna M. P., di Liberto D. D., Dieli F., Caccamo N. Functional signatures of human CD4 and CD8 T cell responses to Mycobacterium tuberculosis. Frontiers in Immunology. 2014;5, article 180
Wynn T. A. Fibrotic disease and the TH1/TH2 paradigm. Nature Reviews Immunology. 2004;4(8):538–594.
Quigley K. J., Reynolds C. J., Goudet A., et al. Chronic infection by mucoid pseudomonas aeruginosa associated with dysregulation in T-cell immunity to outer membrane porin F. American Journal of Respiratory and Critical Care Medicine. 2015;191(11):1250–1264.
Knutsen A. P., Bush R. K., Demain J. G., et al. Fungi and allergic lower respiratory tract diseases. The Journal of Allergy and Clinical Immunology. 2012;129(2):280–291.
Mallia P., Footitt J., Sotero R., et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2012;186(11):1117–1124.
Gao Y.-H., Guan W.-J., Xu G., et al. The role of viral infection in pulmonary exacerbations of bronchiectasis in adults: A prospective study. CHEST. 2015;147(6):1635–1643.
Pizzutto S. J., Upham J. W., Yerkovich S. T., Chang A. B., Tregoning J. S. High Pulmonary Levels of IL-6 and IL-1β in Children with Chronic Suppurative Lung Disease Are Associated with Low Systemic IFN-γ Production in Response to Non-Typeable Haemophilus influenzae. PLoS ONE. 2015;10(6):p. e0129517.
Chang A. B., Bell S. C., Torzillo P. J., et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Medical Journal of Australia. 2015;202(3):p. 130.
Polverino E., Goeminne P. C., McDonnell M. J., et al. European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal. 2017;50(3):p. 1700629.
Tarzi M. D., Grigoriadou S., Carr S. B., Kuitert L. M., Longhurst H. J. Clinical immunology review series: An approach to the management of pulmonary disease in primary antibody deficiency. Clinical & Experimental Immunology. 2009;155(2):147–155.
Stubbs A., Bangs C., Shillitoe B., et al. Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy. Clinical & Experimental Immunology. 2018;191(2):212–219.
Welsh E. J., Evans D. J., Fowler S. J., Spencer S. Interventions for bronchiectasis: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews. 2015;7:p. CD010337.
Serisier D. J., Martin M. L., McGuckin M. A., et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. Journal of the American Medical Association. 2013;309(12):1260–1267.
Hodge S., Tran H. B., Hamon R., et al. Nonantibiotic macrolides restore airway macrophage phagocytic function with potential anti-inflammatory effects in chronic lung diseases. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2017;312(5):L678–L687.
Polverino E., Rosales-Mayor E., Dale G. E., Dembowsky K., Torres A. The Role of Neutrophil Elastase Inhibitors in Lung Diseases. CHEST. 2017;152(2):249–262.
Konstan M. W., Ratjen F. Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis. Journal of Cystic Fibrosis. 2012;11(2):78–83.
O'Donnell A. E., Barker A. F., Ilowite J. S., Fick R. B. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. CHEST. 1998;113(5):1329–1334.
Brinkmann V., Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin? The Journal of Cell Biology. 2012;198(5):773–783.
Yildirim I., Shea K. M., Pelton S. I. Pneumococcal disease in the era of pneumococcal conjugate vaccine. Infectious Disease Clinics of North America. 2015;29(4):679–697.
Pizzutto S. J., Yerkovich S. T., Upham J. W., Hales B. J., Thomas W. R., Chang A. B. Improving immunity to Haemophilus influenzae in children with chronic suppurative lung disease. Vaccine. 2015;33(2):321–326.
Khamdamov B. Z., Ganiev A. A., Khamdamov I. B. The role of cytokines in the immunopatogenesis of acute pancreatitis //Journal of Survey in Fisheries Sciences. – 2023. – Т. 10. – №. 2S. – С. 3949-3958.
Davlatov S. S., Khamdamov B. Z., Teshaev S. J. Neuropathic form of diabetic foot syndrome: etiology, pathogenesis, classifications and treatment (literature review) //Journal of Natural Remedies. – 2021. – Т. 22. – №. 1 (2). – С. 147-156.
